FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:190-192 July 13, 2006 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Barrett-Connor, E. PubMed Citation

During the past decade, considerable scientific, clinical, and public interest in the benefits and risks of postmenopausal estrogen therapy has focused attention on selective estrogen-receptor modulators (SERMs). These act as estrogen agonists in some tissues and antagonists in others because of specific actions on at least two distinct estrogen receptors, the proportions of which differ across tissues. As such, SERMs have held the promise of conferring benefits similar to those associated with estrogen therapy, including a reduced risk of osteoporosis, while simultaneously reducing estrogen-related risks (e.g., invasive breast cancer). The once widely held belief that estrogen therapy was cardioprotective¹ also . . . [Full Text of this Article]

Source Information

From the Stanford Prevention Research Center, Stanford School of Medicine, Stanford, Calif.

This article has been cited by other articles:

• (2006). Raloxifene Does Not Prevent Heart Disease. Journal Watch Cardiology 2006: 2-2 [Full Text]  
• (2006). Raloxifene and Risk for Cardiovascular Events and Breast Cancer. JWatch Women's Health 2006: 1-1 [Full Text]  
• (2006). Outcomes with Raloxifene in Women with Above-Average Coronary Risk. JWatch General 2006: 1-1 [Full Text]